ArticleFrontiers in oncology2025
Anlotinib for the treatment of recurrent and refractory hemangioblastomas: a case report and review of literature.
Qing Tian et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it